by wilheminamancia | Oct 14, 2023 | Health & Fitness, Cardio
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky.”I encourage parents of teens...
Recent Comments